Morgan Stanley Call 410 AMGN 20.1.../ DE000ME86144 /
2024-05-31 10:59:00 AM | Chg.+0.010 | Bid12:08:21 PM | Ask12:08:21 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.320EUR | +3.23% | 0.350 Bid Size: 750 |
- Ask Size: - |
Amgen Inc | 410.00 USD | 2024-12-20 | Call |
GlobeNewswire
05-30
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affa...
GlobeNewswire
05-28
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
GlobeNewswire
05-27
Samsung Bioepis Announces Oral Presentation on Switching Period Results for SB16, a Proposed Biosimi...
GlobeNewswire
05-23
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine recept...
GlobeNewswire
05-22
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...
GlobeNewswire
05-21
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
GlobeNewswire
05-21
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a bios...
GlobeNewswire
05-15
Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
GlobeNewswire
05-14
Accumulus Synergy Sponsors Revolutionary Healthcare Data Standard, Advancing Towards Global Dossier
GlobeNewswire
05-14
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...
GlobeNewswire
05-13
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
05-09
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-08
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 ...
GlobeNewswire
05-08
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-08
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination ...